

Freedom of Information Team
Post Room
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Date: 19/10/2021

Ref: 21-22 337

Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 27/09/2021. Please see responses to your requests below.

- 1. For the 4-month period from May to August 2021, how many patients has your trust treated with the following anti-VEGF treatments:**

Treatment:	Patients:
Aflibercept	950
Bevacizumab	61
Brolucizumab	0
Dexamethasone	37
Fluocinolone acetonide	0
Ranibizumab	164

- 2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.**

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

The Trust is only able to provide information in relation to drug dispensing, we do not record diagnoses on our clinical systems so therefore we are unable to link the type of drug to diagnosis or treatments.

To extract this information, the Trust would have to search through a significant amount of patient records. It is estimated that to attempt to retrieve all the information you require would take a considerable amount of retrieval time, which would exceed 18 hours. This would exceed the appropriate limit for dealing with a Freedom of Information Request, in terms of costs and therefore Section 12(1) of the Freedom of Information Act 2000 applies.

3. **Within your trust, how many intra-vitreous injections/implants of each following treatments have been used (for any eye condition) in the four-month period from May to August 2021:**
- **Aflibercept**
 - **Bevacizumab**
 - **Brolucizumab**
 - **Dexamethasone**
 - **Ranibizumab**

Please see answer in question 2.

4. **If your trust is able to identify intra-vitreous injections/implants by eye condition, please provide the number of injections/implants used in the four-month period from May to August 2021 for Wet Age Related Macular Degeneration (wAMD) ONLY**

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Ranibizumab**

Please see answer in question 2.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team